Ifol

# Ifol ## Overview - **Classification**: Novel Anticoagulant (NOAC), Selective Factor Xa Inhibitor - **Mechanism**: Potently and selectively inhibits free and clot-bound Factor Xa, an enzyme critical for the coagulation cascade, preventing thrombin generation and clot formation. ## Primary Indications 1. **Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation (NVAF)** - For reduction of risk in adult patients. 2. **Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)** - For acute treatment and prevention of recurrence. 3. **Prophylaxis of DVT and PE after Hip or Knee Replacement Surgery** - For prevention in adult patients. ## Adult Dosing ### Standard Dosing **Prevention of Stroke/Systemic Embolism in NVAF** - **Dose**: **20 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Special Considerations**: Administer with evening meal for optimal absorption. **Treatment of DVT/PE** - **Initial Dose**: **15 mg** - **Frequency**: Twice daily (BID) for 21 days - **Route**: Oral - **Subsequent Dose**: **20 mg** once daily (QD) - **Duration**: Typically 3-6 months, or longer for recurrent events. **Prophylaxis of DVT/PE after Hip or Knee Replacement Surgery** - **Dose**: **10 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Duration**: 12 days for knee replacement, 35 days for hip replacement. ### Dose Adjustments - **Renal Impairment**: - CrCl **>50 mL/min**: No dose adjustment. - CrCl **15-50 mL/min**: - NVAF: **15 mg** QD (with evening meal). - DVT/PE treatment: No adjustment needed. - DVT/PE prophylaxis: No adjustment needed. - CrCl **<15 mL/min** or Dialysis: **Avoid use**. - **Hepatic Impairment**: - Child-Pugh A: No dose adjustment. - Child-Pugh B or C: **Avoid use** due to increased bleeding risk. - **Elderly Patients**: No specific dose adjustment solely based on age. Monitor renal function closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Ifol is not approved or recommended for use in neonates.** - **Special Notes**: Safety and efficacy have not been established. Risk of bleeding outweighs potential benefits. ### Infants (1-12 months) - **Ifol is not approved or recommended for use in infants.** - **Special Notes**: Limited data; use only in clinical trials or under expert guidance in severe cases. Potential for increased drug exposure due to immature organ function. ### Children (1-12 years) - **Treatment of VTE (After initial parenteral therapy)** - **Dose**: **0.4 mg/kg** (for body weight 10-20 kg); **0.5 mg/kg** (for body weight >20-30 kg); **0.6 mg/kg** (for body weight >30-50 kg). - **Frequency**: Once daily (QD) - **Route**: Oral - **Maximum**: Do not exceed **20 mg** QD. - **Special Notes**: Use a commercially available **oral suspension** or crush tablets. Administer with food. ### Adolescents (13-18 years) - **Dose**: Typically **adult dosing** as described above, based on indication. - **Maximum**: **20 mg** QD for NVAF/VTE treatment; **10 mg** QD for VTE prophylaxis. - **Special Notes**: Weight should be ≥50 kg. Administer with food for optimal absorption. ## Safety Information ### Contraindications - **Absolute**: Active pathological bleeding (e.g., intracranial hemorrhage, GI bleed). - **Absolute**: Severe hypersensitivity to Ifol. - **Absolute**: Concomitant use with other parenteral anticoagulants (e.g., heparin) unless during transition. - **Relative**: Severe renal impairment (CrCl <15 mL/min) or end-stage renal disease requiring dialysis. - **Relative**: Moderate to severe hepatic impairment (Child-Pugh B or C). ### Common Adverse Effects - **Very Common (>10%)**: Bleeding (epistaxis, GI bleeding), Anemia - **Common (1-10%)**: Nausea, Abdominal pain, Dyspepsia, Peripheral edema, Increased liver enzymes (ALT/AST) - **Serious but Rare**: Major bleeding events (e.g., intracranial, retroperitoneal), Hepatic injury, Allergic reactions (Stevens-Johnson syndrome), Spinal/epidural hematoma (with neuraxial anesthesia). ### Key Drug Interactions - **Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)**: Increase Ifol exposure; **avoid concomitant use** due to increased bleeding risk. - **Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin)**: Decrease Ifol exposure; **avoid concomitant use** due to reduced efficacy. - **Other Anticoagulants (e.g., Warfarin, Heparin)**: Greatly increased bleeding risk; **contraindicated** except for specified transition periods. - **NSAIDs / Antiplatelet Agents (e.g., Aspirin, Clopidogrel)**: Increased bleeding risk; use with **caution** and monitor closely. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (CrCl), Liver function tests (ALT/AST, bilirubin), Complete Blood Count (CBC) including hemoglobin and platelets. - **During Treatment**: - **Renal function**: Periodically (e.g., annually, or more frequently if decline is suspected). - **CBC**: Periodically, especially if bleeding is suspected. - **Clinical Signs**: Regularly assess for signs of bleeding (bruising, melena, hematuria) or thrombotic events. - **Clinical Signs**: Patients should be advised to report unusual bruising, prolonged bleeding from cuts, nosebleeds, blood in urine or stool, or severe headaches immediately. ## Clinical Pearls - 💡 **Timing**: Always take Ifol **with food** (especially the evening meal for 20 mg dose) to improve absorption and ensure consistent drug levels. - 💡 **Missed Dose**: If a dose is missed, take it as soon as remembered on the same day. Do not double the dose to make up for a missed one. - 💡 **Bleeding Risk**: Educate patients on bleeding signs and symptoms and advise avoiding high-risk activities or trauma. - 💡 **Swallowing**: For patients unable to swallow tablets, tablets may be crushed and mixed with water or applesauce immediately before use. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.